We evaluated CTCs from NSCLC and HNC patients, for a marker used to guide patient selection for immune therapy (PD‐L1), CTC chromosomal architecture using molecular probes (ALK translocations, EGFR), the cell junction component plakoglobin, and the presence of CTC clusters. Here, ALK is linked to non-small cell lung carcinoma.